Skip to Content
  • MyChart

    Log in to our secure, personalized website to manage your care (formerly myMDAnderson).

  • Request an Appointment

    If you are ready to make an appointment, select a button on the right. If you have questions about UT MD Anderson’s appointment process, our information page may be the best place to start.

    Appointment Information
    New Patients Current Patients Referring Physicians
  • Every Breakthrough
    Begins With You

    Gifts to UT MD Anderson’s historic philanthropic campaign help accelerate discovery, transform lives and bring hope to more patients than ever before.

    Learn more about Only Possible Here
    Donate Today only-possible-here-logo
The University of Texas MD Anderson Cancer Center
  • Clinical Trials
  • Locations
  • Careers
  • Contact Us
  • Our Doctors
    • Español
    • عربى
    • 中文
    • Türkçe
Clear
close
      MyChart
      Donate Today
      • Clinical Trials
      • Locations
      • Careers
      • Contact Us
        • Español
        • عربى
        • 中文
        • Türkçe
      • Request an Appointment
      • New Patients
      • Current Patients
      • Referring Physicians
      • Patients & Family
          • Becoming Our Patient Home
          • Why UT MD Anderson
          • Planning for Care
          • Getting to UT MD Anderson
          • While You're Here
          • International Center
          • Services and Amenities
          • Insurance & Billing
          • Second Opinion Appointments
          • Diagnosis & Treatment Home
          • Cancer Types
          • A New Diagnosis
          • Treatment Options
          • Care Centers & Clinics
          • Emotional & Physical Effects
          • Patient Support
          • Clinical Trials
          • Supporting a Loved One Home
          • Caregiver Roles & Challenges
          • Children and Teens
          • Taking Care of Yourself
          • Helping a UT MD Anderson Patient
          • Dealing with Loss
          • Life After Cancer Home
          • Follow-up Care After Cancer Treatment
          • Long-Term Effects of Cancer
          • Social & Emotional Impacts of Cancer
          • Legal & Financial Impacts of Cancer
          • Survivorship Week
        • Request an Appointment Current Patients

          Find information and resources for current and returning patients.

          Clinical Trials

          Learn about clinical trials at UT MD Anderson and search our database for open studies.

      • Prevention & Screening
          • Manage Your Risk Home
          • Tobacco Control
          • Diet
          • Body Weight
          • Physical Activity
          • Skin Safety
          • HPV
          • Hepatitis
          • Alcohol
          • Family History Home
          • Genetic Testing
          • Hereditary Cancer Syndromes
          • Genetic Counseling and Testing FAQs
          • Cancer Screenings Home
          • Mammograms & Breast Cancer Screening
          • Cervical Cancer Screening
          • Colorectal Cancer Screening
          • Endometrial Cancer Screening
          • Liver Cancer Screening
          • Lung Cancer Screening
          • Mobile Mammography
          • Ovarian Cancer Screening
          • Prostate Cancer Screening
          • Skin Cancer Screening
          • Women's Cancer Screening
          • Men's Cancer Screening
        • Cancer Prevention Center 

          The Lyda Hill Cancer Prevention Center provides cancer risk assessment, screening and diagnostic services.

      • Donors & Volunteers
          • Donate Home
          • Raise Money
          • Honor Loved Ones
          • Create Your Legacy
          • Endowments
          • Caring Fund
          • Matching Gifts
          • Foundation and Corporation Relations
          • Volunteer Home
          • Why Volunteer
          • On-Site Volunteers
          • Volunteer Endowment
          • Patient Experience
          • Teen Volunteer Leadership Program
          • Children's Cancer Hospital Councils
          • Other Ways to Help Home
          • Give Blood
          • Shop UT MD Anderson
          • Children's Art Project
          • Donate Goods or Services
          • Attend Events
          • Cord Blood Bank
          • Corporate Alliances Home
          • Current Alliances
        • Join the Campaign to End Cancer 

          Help us celebrate and fuel the groundbreaking innovations and transformative advancements that define UT MD Anderson.

      • For Physicians
          • Refer a Patient Home
          • Health Care Provider Resource Center
          • Referring Provider Team
          • Insurance Information
          • International Referrals
          • myMDAnderson for Physicians
          • Second Opinion Pathology
          • Clinical Trials Home
          • Clinical Tools & Resources Home
          • Clinical Calculators
          • Clinical Practice Algorithms
        • myMDAnderson for Physicians 

          Our personalized portal helps you refer your patients and communicate with their UT MD Anderson care team.

      • Research
          • Departments, Labs and Institutes Home
          • Departments and Divisions
          • Labs
          • Research Centers and Programs
          • Institutes
          • Specialized Programs of Research Excellence (SPORE) Grants
          • Research Areas Home
          • Basic Science
          • Translational Research
          • Clinical Research
          • Prevention & Personalized Risk Assessment
          • Research Resources Home
          • Excellence in Science
          • Core Facilities and Services
          • Conferences & Seminars
          • Why Research at UT MD Anderson
          • STRIDE
          • NCI-Designated Cancer Center
          • Data Resources
        • Clinical Trials 

          As part of our mission to eliminate cancer, UT MD Anderson researchers conduct hundreds of clinical trials to test new treatments for both common and rare cancers.

      • Education & Training
          • Degree-Granting Schools Home
          • School of Health Professions
          • MD Anderson UTHealth Houston Graduate School
          • Research Training Home
          • Early Career Pathway Programs
          • Predoctoral Training
          • Postdoctoral Training
          • Mentored Faculty Programs
          • Career Development
          • Clinical Training Home
          • Graduate Medical Education
          • Clinical Education for Non-Physicians
          • Nursing Education & Training
          • Continuing Education & Review Courses
          • Simulation Center
          • Continuing Education & Professional Development Home
          • Continuing Professional Education/Conferences
          • Administrative Internships & Fellowships
          • Cancer Survivorship Professional Education
          • Leadership Institute
          • Patient Home Visits
          • Education Resources Home
          • Alumni Relations
          • Education Design Services
          • Awards & Recognitions
          • Academic Mentoring Council
          • Why UT MD Anderson & Houston
          • Outreach Programs Home
          • Project ECHO
          • Observer Programs
          • Comparative Effectiveness Training (CERTaIN)
          • Faculty Speakers Bureau
        • Apply to SHP

          Choose from 12 allied health programs at School of Health Professions.

          Research Trainees

          View open postdoctoral and other research trainee positions.

          GME Fellowships

          Learn about our graduate medical education residency and fellowship opportunities.

      Farhad R. Danesh Image

      Farhad R. Danesh, M.D.

      Department of Emergency Medicine, Division of Internal Medicine

      About Dr. Danesh

      The primary interest of our research group is to delineate the molecular mechanisms through which diabetic nephropathy progresses, and to identify and characterize novel molecular targets that could potentially prevent progression of diabetic kidney disease. We utilize animal models of diabetes to accomplish these ambitious goals. Along these lines, we aim to examine the novel regulatory factors that lead to the development and/or progression of diabetic nephropathy. We are currently testing two broad objectives. The first is to gain insight into the pathobiology of mitochondria in the kidneys. In particular, we want to understand the biological functions of mitochondrial dynamics and how disrupting the functions of mitochondria contribute to the pathogenesis of diabetic kidney disease. Our group discovered that mitochondrial dynamics is a major molecular mechanism implicated in glucose-mediated microvascular organ damage (Wang W et al. Cell Met. 2012,15:186-200).. This has created a paradigm shift in the field. The second is to understand the regulatory effects of microRNAs in microvascular complications of diabetes. Our laboratory has been on the forefront of identifying multiple miRNAs and their downstream effectors in the kidney. We have recently published novel observations on the potential effects of miRNAs in diabetic nephropathy (Long J. et al: J. Biol. Chem . 2010, 285:23457–23465; and Long J. et al: J. Biol. Chem. 2011, 286: 11837-11848). These collective efforts have significantly accelerated the process of assessing the role of miRNAs in the pathobiology of diabetic nephropathy. Collectively, our research paradigm uses a combined approach of molecular genetics, genomics and epigenomics to understand the underlying pathological and molecular basis of diabetic nephropathy.

      Read More

      Meet Farhad Danesh, M.D.

      Present Title & Affiliation

      Primary Appointment

      Professor of Medicine with Tenure, Section of Nephrology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, Houston, TX

      Chief, Section of Nephrology, Section of Nephrology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, Houston, TX

      Adjunct Professor of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, TX, Houston, TX

      Professor of Medicine with tenure, Department of Internal Medicine, Division of Nephrology, Baylor College of Medicine, Houston, TX, Houston, TX

      Dual/Joint/Adjunct Appointment

      Adjunct Professor of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, TX

      Professor of Medicine with tenure, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

      Professor of Medicine with tenure, Department of Internal Medicine, Division of Nephrology, Baylor College of Medicine, Houston, TX

      Research Interests

      1. Rho GTPases
      2. Mitochondria
      3. microRNAs
      4. Long non-coding RNAs
      5. Cisplatin-induced nephrotoxicity
      6. Diabetic nephropathy

      Education & Training

      Degree-Granting Education

      1989University of Alcala Medical School, Madrid, ES, MD

      Postgraduate Training

      1998-1999Nephrology Research Fellowship, Laboratory of Daniel Batlle, MD, Northwestern University Medical School, Chicago, Illinois
      1996-1998Nephrology Clinical Fellowship, Northwestern University Medical School, Chicago, Illinois
      1993-1996Internship/Residency, University of Chicago / Weiss Memorial Hospital Program, Chicago, Illinois
      1991-1992Cancer Research Fellowship, Laboratory of Yaacov Ben-David, MD, University of Toronto, Toronto

      Licenses & Certifications

      2024Mississippi State Board of Medical Licensure
      2024Georgia Composite Medical Board
      2024Oklahoma State Board of Medical Licensure
      2024Alabama Board of Medical Examiners
      2024Tennessee Board of Medical Examiners
      2023Arizona Board of Medical Examiners
      2023Washington State Department of Health
      2023Louisiana State Board of Medical Examiners
      2021Florida Board of Medicine
      2013Drug Enforcement Administration
      1999American Board of Nephrology
      1996Texas Medical Board
      1996American Board of Internal Medicine
      1993Educational Commission for Foreign Medical Graduates
      1993Illinois Medical License

      Experience & Service

      Faculty Academic Appointments

      Professor of Pharmacology, Baylor College of Medicine, Houston, TX, 2012 - 2013

      Associate Professor of Pharmacology, Baylor College of Medicine, Houston, TX, 2008 - 2012

      Associate Professor with tenure, Baylor College of Medicine, Houston, TX, 2007 - 2012

      Assistant Professor of Medicine, Northwestern University, Chicago, IL, 2001 - 2007

      Instructor of Medicine, Northwestern University, Chicago, IL, 1999 - 2001

      Administrative Appointments/Responsibilities

      Chief, Section of Nephrology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - Present

      Director, Inpatient Dialysis, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - 2017

      Extramural Institutional Committee Activities

      Member, Infectious Diseases, Infection Control and Employee Health Chair Search Committee, The University of Texas MD Anderson Cancer Center, 2021 - 2022

      Member, Promotion and Tenure Committee, The University of Texas MD Anderson Cancer Center, 2021 - 2024

      Member, Research Committee, The University of Texas MD Anderson Cancer Center, 2016 - 2018

      Chair, Dialysis Steering Committee, The University of Texas MD Anderson Cancer Center, 2015 - 2019

      Chair, Distinguished Paper Award Committee, The University of Texas MD Anderson Cancer Center, 2015 - 2018

      Member, Internal Medicine Research Committee, MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2013 - Present

      Standing Member, Pathobiology of Kidney Disease Study Section, Bethesda, MD, National Institutes of Health, 2010 - 2015

      Member, NIDDK RFA-DK-08-015. Chronic Kidney Disease Biomarker Discovery, National Institutes of Health, 2009 - Present

      Member, American Foundation for Medical Research, American Foundation for Medical Research, 2008 - 2010

      Member, NIDDK PBKD Special Emphasis Panel, National Institutes of Health, 2007 - Present

      Member, Research Grant Committee, National Kidney Foundation, 2007 - 2014

      Member, Committee on Scientific Integrity, Baylor College of Medicine, 2007 - 2012

      Standing Member, Merit Review Subcommittee for Nephrology, Department of Veterans Affairs, 2007 - 2012

      Member, Member, NIH/NIDDK Renal & Urological Sciences-B Study Section, ZRG1-RUS-B, National Institutes of Health, 2006

      Member, Scientific Advisory Committee (SAC), Northwestern University, 2005 - 2007

      Member, NIDDK Study Section, RFA-ZDK M1 Animal Models of Diabetic Complications, National Institutes of Health, 2005

      Member, NIDDK Study Section, RFA-ZDK GRB-4 Angiogenesis & Diabetic Complications, National Institutes of Health, 2005

      Member, Faculty Committee, Northwestern University, 2004 - 2007

      Member, Northwestern Medical Faculty Foundation, Northwestern University, 1999 - 2005

      Organizing Member, Program Committee, Annual Scientific Meeting of the American Society of Nephrology, American Society of Nephrology

      Chair, NIDDK ZDK1 GRB-S Study Section, National Institutes of Health

      Co-Chair, NIDDK ZRG1 KUDS-H Special Emphasis Study Section, National Institutes of Health

      Editorial Activities

      Associate Editor, Journal of American Society of Nephrology, 2026 - Present

      Editorial Board, Journal of Biological Chemistry, 2024 - 2029

      Editorial Board, Frontiers in Pharmacology, 2022 - Present

      Editorial Board, Diabetes, 2020 - 2024

      Editorial Board, Journal of American Society of Nephrology, 2015 - 2019

      Editorial Board, Kidney International, 2013 - Present

      Editorial Board, Physiological Genomics, 2012 - 2022

      Honors & Awards

      2022Distinguished Achievement Award, American University of Beirut
      2018Investigator Award, Chinese Society of Nephrology
      2017Distinguished Research Award, Korean Society of Nephrology
      2016Distinguished Investigator, Japanese Society of Nephrology
      2001 - 2002Merck Medical School Award, Merck & Company
      2000Northwestern Hospital Intramural Award, Northwestern Hospital
      1998Bristol-Myers Squibb Research Award, Bristol-Myers Squibb
      1996Outstanding Teaching Award, Weiss Memorial Hospital

      Professional Memberships

      American Heart Association - Council on Kidney in Cardiovascular Disease

      2026 - Present

      American Society of Onco-Nephrology

      2021 - Present

      National Kidney Foundation

      2008 - Present

      American Heart Association Western Affiliate Research Grant Committee

      2008 - 2010

      American Foundation for Medical Research

      2008 - 2010

      American Heart Association - Council on Kidney in Cardiovascular Disease

      2008 - 2010

      American Society of Nephrology

      1998 - Present

      Selected Presentations & Talks

      Local Presentations

      1. 2025. Electron Transport Chain Remodeling in Diabetic Kidney Disease. Invited. Albany Medical College Department of Regenerative & Cancer Cell Biology Seminar. Albany, NY, US.
      2. 2024. The Role of Electron Transport Chain Remodeling in Diabetic Kidney Disease. Invited. Augusta University Cellular Biology and Anatomy Seminar Series. Augusta, GA, US.

      National Presentations

      1. 2025. Post-Transcriptional and Post-Translational Processing in Glomerular Diseases. Invited. American Society of Nephrology, Annual Meeting. Houston, TX, US.
      2. 2024. Mitochondrial Complex I Assembly Factor NDUFAF1 Regulates Tubulointerstitial Fibrosis in Diabetic Kidney Disease via a Tricarboxylic Acid Cycle Metabolite. Invited. American Society of Nephrology, Annual Meeting. San Diego, CA, US.
      3. 2023. The Transcription Factor ChREBP Links Mitochondrial Lipidomes to Mitochondrial Morphology and Progression of Diabetic Kidney Disease. Invited. American Society of Nephrology, Annual Meeting. Philadelphia, PA, US.
      4. 2023. NDUFS4 Regulates Cristae Remodeling in Diabetic Kidney Disease. Invited. American Society of Nephrology, Annual Meeting, US.
      5. 2019. Deletion of Proximal Tubular Cell VEGF Production Promotes Renal Fibrosis: Implications for VEGF-Based Cancer Therapy. Poster. American Society of Nephrology, Annual Meeting. Washington, DC, US.
      6. 2019. Deletion or Inhibition of ARF6 Improves Albuminuria in Type 2 Diabetic Mice. Poster. American Society of Nephrology, Annual Meeting. Washington, DC, US.
      7. 2019. CAR-T Cells, Checkpoint Inhibitors and the Kidney. Invited. Nephrology for the Consultant with Annual Nephrology Young Investigators Forum. San Diego, CA, US.
      8. 2019. Kidney Effects of Newer Anticancer Agents. Invited. Nephrology for the Consultant with Annual Nephrology Young Investigators Forum. San Diego, CA, US.
      9. 2018. Mice with Drp1-S600 Knockin Mutation Exhibit Reduced Mitochondrial Fission and Attenuation of Diabetic Nephropathy. Invited. American Society of Nephrology, Annual Meeting. San Diego, CA, US.
      10. 2018. Mitochondial Reprogramming in Diabetic Nephropathy. Conference. Keystone Symposia. Santa Fe, NM, US.
      11. 2017. TMA and Onconephrology. Invited. Onco-Nephrology Symposium. New York, NY, US.
      12. 2015. Mitochondrial Regulation in the Glomerulus. Invited. American Society of Nephrology, Annual Meeting. San Diego, CA, US.
      13. 2015. Renal Consults from the Oncology Floor. Invited. American Society of Nephrology, Annual Meeting. San Diego, CA, US.
      14. 2012. Complications of Diabetes. Invited. Keystone Symposia, US.
      15. 2011. ROCK1 Promotes Diabetic Nephropathy by Triggering Mitochondrial Fission Through Serine Phosphorylation of Drp1. Invited. American Society of Nephrology, Annual Meeting. Philadelphia, PA, US.
      16. 2010. MicroRNA-29c Targets Sprouty1, Promotes Apoptosis and fibrosis, and its Inhibition Prevents Progression of Diabetic Nephropathy. Invited. American Society of Nephrology, Annual Meeting. Denver, CO, US.
      17. 2010. Targeted deletion of ROCK1 confers renoprotection in diabetic nephropathy. Invited. American Society of Nephrology, Annual Meeting. Denver, CO, US.
      18. 2010. Identification of microRNA-93 as a novel regulator of vascular endothelial growth factor (VEGF) in hyperglycemic conditions. Invited. American Society of Nephrology, Annual Meeting. Denver, CO, US.
      19. 2009. Micromanaging VEGF by microRNA-93 in Diabetes. Invited. American Society of Nephrology, Annual Meeting. San Diego, CA, US.
      20. 2008. Deletion of Scavenger Receptor A I/II Ameliorates Tubulointerstitial Fibrosis in UUO Mice with Diet-Induced Hypercholesterolemia. Invited. American Society of Nephrology, Annual Meeting. Philadelphia, PA, US.
      21. 2008. Synthetic Nanofibers Confer Renoprotection Via Delivery of Cytokines Released from Embryonic Stem Cells. Invited. American Society of Nephrology, Annual Meeting. Philadelphia, PA, US.
      22. 2008. Role of Rap1b GTPase in Modulation of High Glucose-Induced Renal Mitochondrial Injury. Invited. American Society of Nephrology, Annual Meeting. Philadelphia, PA, US.

      International Presentations

      1. 2019. Role of Mitochondria in Diabetic Nephropathy. Invited. keystone symposia. Whistler, British Columbia, CA.
      2. 2018. Renal Cell Carcinoma. Conference. KDIGO Onconephrology. Milan, IT.
      3. 2018. Onconephrology. Invited. 2018 Xiangya Kidney disease Forum. Changsha, CN.
      4. 2017. Nephrotoxicity from cytotoxic agents. Conference. International Conference OncoNephrology. Naples, IT.
      5. 2016. Mitochondrial Dysfunction in Diabetic Nephropathy. Invited. University of Tokyo. Tokyo, JP.
      6. 2013. Diabetic Nephropathy-Signaling. Invited. World Diabetes Congress. Melbourne, AU.
      7. 2013. MicroRNAs in Diabetic Nephropathy. Invited. World Diabetes Congress. Melbourne, AU.

      Formal Peers

      1. 2016. Mitochondrial Dysfunction in Diabetic Nephropathy. Visiting. Osaka, JP.
      2. 2016. Renal Grand Rounds. Invited. San Antonio, TX, US.
      3. 2016. Medicine Grand Rounds. Invited. San Antonio, TX, US.
      4. 2015. Diabetes, Heart and Kidneys. Visiting. Madrid, ES.
      5. 2013. World Diabetes Conference. Visiting, AU.
      6. 2013. Grand Rounds. Invited. Charlottesville, VA, US.
      7. 2013. The 4th International Symposium on Dynamics of Mitochondria. Visiting, JP.
      8. 2012. ERA-EDTA Annual Meeting. Visiting. Paris, FR.
      9. 2012. IBT Grand Rounds. Invited, US.
      10. 2012. Renal Grand Rounds. Invited, US.
      11. 2012. Pharmacology and Cell Biology. Invited, US.
      12. 2012. Nephrology Grand Round. Invited, US.
      13. 2011. Nephrology Grand Round. Invited, US.
      14. 2011. MicroRNA Lecture Series. Invited, US.
      15. 2011. Medicine Grand Rounds. Invited, US.
      16. 2011. Nephrology Grand Round. Invited, US.
      17. 2010. Nephrology. Invited, US.
      18. 2010. Nephrology. Invited, US.
      19. 2010. Nephrology Grand Round. Invited, US.
      20. 2009. Diabetes. Invited, US.
      21. 2009. Pharmacology. Invited, US.
      22. 2008. Scientific Meeting. Invited, US.
      23. 2007. Nephrology Grand Rounds. Invited, US.
      24. 2007. Nephrology Grand Rounds. Invited, US.
      25. 2006. Nephrology. Invited, US.
      26. 2006. Pediatric Care. Invited, US.
      27. 2005. Nephrology. Invited, US.
      28. 2005. Medicine Grand Rounds. Invited, US.
      29. 2005. Nephrology Grand Rounds. Invited, US.
      30. 2005. Diabetes, Heart and Kidneys. Invited, US.
      31. 2004. Endocrinology Grand Rounds. Invited, US.
      32. 2004. Dept. of Medicine Research Grand Rounds. Invited, US.
      33. 2004. Renal Grand Rounds. Invited, US.
      34. 2002. Nephrology. Invited, US.
      35. 2001. Endocrinology Grands Rounds. Invited. Chicago, US.
      36. 2001. Nephrology. Invited, US.
      Read More
      Less

      Grant & Contract Support

      Date: 2025 - 2030
      Title:Regulation of Mitochondrial Respiration in Diabetic Kidney Disease
      Funding Source:NIH/NIDDK
      Role:PI
      ID:RO1DK142664-01
      Date: 2019 - 2024
      Title:Role of ARF6 in the Progression of Diabetic Kidney Disease
      Funding Source:NIH/NCI
      Role:Mentor
      ID:1K08DK119466-01
      Date: 2011 - 2025
      Title:MicroRNAs in diabetic nephropathy
      Funding Source:NIH/NIDDK
      Role:PI
      ID:1R01DK091310
      Date: 2007 - 2025
      Title:Rho Kinases in diabetic nephropathy
      Funding Source:NIH/NIDDK
      Role:PI
      ID:5R01DK078900
      Date: 2005 - 2010
      Title:Statins-VEGF induced cytoskeletal remodeling
      Funding Source:NIH/NIDDK
      Role:PI
      ID:R01DK067604-05
      Date: 2004 - 2007
      Title:Mechanisms of action and effects in diabetic nephropathy
      Funding Source:American Diabetes Association
      Role:PI
      ID:1-03-RA-15
      Date: 2003 - 2008
      Title:Pathobiology of HMG-CoA Reductase Inhibitors in Diabetes
      Funding Source:NIH/NIDDK
      Role:Co-PI
      ID:R01DK028492
      Date: 1991 - 2009
      Title:Glomerular capillary wall-normal and pathologic
      Funding Source:NIH/NIDDK
      Role:Co-I
      ID:R01DK028492

      Selected Publications

      Peer-Reviewed Articles

      1. Si M, Chen J, Yu R, Lin H, Li F, Jung S, Thomas SS, Danesh FR, Wang Y, Peng H, Hu Z. Protein kinase ROCK1 activates mitochondrial fission linking to oxidative stress and muscle atrophy. Kidney Int 108(4):626-641, 2025. e-Pub 2025. PMID: 40505862.
      2. Ramasamy C, Neelamegam K, Ramachandran S, Xia H, Kapusta DR, Danesh FR, Pandey KN. Podocyte cell-specific Npr1 is required for blood pressure and renal homeostasis in male and female mice: role of sex-specific differences. Physiol Genomics 56(10):672-690, 2024. e-Pub 2024. PMID: 39101921.
      3. Mise K, Long J, Galvan DL, Ye Z, Fan G, Sharma R, Serysheva II, Moore TI, Jeter CR, Anna Zal M, Araki M, Wada J, Schumacker PT, Chang BH, Danesh FR. NDUFS4 regulates cristae remodeling in diabetic kidney disease. Nat Commun 15(1):1965, 2024. e-Pub 2024. PMID: 38438382.
      4. Danesh FR, Mamlouk O. Immune Checkpoint Inhibitor-Associated Nephrotoxicity. Nephron 148(1):11-15, 2024. e-Pub 2023. PMID: 37257429.
      5. Li L, Long J, Mise K, Poungavrin N, Lorenzi PL, Mahmud I, Tan L, Saha PK, Kanwar YS, Chang BH, Danesh FR. The transcription factor ChREBP links mitochondrial lipidomes to mitochondrial morphology and progression of diabetic kidney disease. J Biol Chem 299(9):105185, 2023. e-Pub 2023. PMID: 37611830.
      6. Danesh F, Mise K, Long J, Galvan D, Ye Z, Fan G, Serysheva I, Moore T, Wada J, Schumacker P, Chang B. NDUFS4 Regulates Cristae Remodeling in Diabetic Kidney Disease. Res Sq, 2023. e-Pub 2023. PMID: 37461606.
      7. Long J, Danesh FR. Promises and challenges of miRNA therapeutics. Am J Physiol Renal Physiol 323(6):F673-F674, 2022. e-Pub 2022. PMID: 36264885.
      8. Li L, Long J, Mise K, Galvan DL, Overbeek PA, Tan L, Kumar SV, Chan WK, Lorenzi PL, Chang BH, Danesh FR. PGC1α is required for the renoprotective effect of lncRNA Tug1 in vivo and links Tug1 with urea cycle metabolites. Cell Rep 36(6):109510, 2021. e-Pub 2021. PMID: 34380028.
      9. Li L, Sun L, Danesh FR. The multifaceted contributions of long noncoding RNAs on mitochondrial dysfunction in diabetic nephropathy. Diabet Nephrop 1(1):5-8, 2021. e-Pub 2021. PMID: 34690415.
      10. Malyszko J, Bamias A, Danesh FR, Debska-Slizien A, Gallieni M, Gertz MA, Kielstein JT, Tesarova P, Wong G, Cheung M, Wheeler DC, Winkelmayer WC, Porta C, Participants C. KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation. Kidney Int 98(6):1407-1418, 2020. e-Pub 2020. PMID: 33276867.
      11. Long J, Galvan DL, Mise K, Kanwar YS, Li L, Poungavrin N, Overbeek PA, Chang BH, Danesh FR. Role for carbohydrate response element-binding protein (ChREBP) in high glucose-mediated repression of long noncoding RNA Tug1. J Biol Chem 295(47):15840-15852, 2020. e-Pub 2020. PMID: 32467232.
      12. Porta C, Bamias A, Danesh FR, Debska-Slizien A, Gallieni M, Gertz MA, Kielstein JT, Tesarova P, Wong G, Cheung M, Wheeler DC, Winkelmayer WC, Malyszko J, Participants C. KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer. Kidney Int 98(5):1108-1119, 2020. e-Pub 2020. PMID: 33126977.
      13. Capasso A, Benigni A, Capitanio U, Danesh FR, Di Marzo V, Gesualdo L, Grandaliano G, Jaimes EA, Malyszko J, Perazella MA, Qian Q, Ronco P, Rosner MH, Trepiccione F, Viggiano D, Zoccali C, Capasso G, Onco-Nephrology Participants ICO. Summary of the International Conference on Onco-Nephrology: an emerging field in medicine. Kidney Int 96(3):555-567, 2019. e-Pub 2019. PMID: 31445584.
      14. Green NH, Galvan DL, Badal SS, Chang BH, LeBleu VS, Long J, Jonasch E, Danesh FR. MTHFD2 links RNA methylation to metabolic reprogramming in renal cell carcinoma. Oncogene 38(34):6211-6225, 2019. e-Pub 2019. PMID: 31289360.
      15. Sun L, Pan X, Wada J, Haas CS, Wuthrich RP, Danesh FR, Chugh SS, Kanwar YS. Withdrawal: Isolation and functional analysis of mouse UbA52 gene and its relevance to diabetic nephropathy. J Biol Chem 294(26):10382, 2019. e-Pub 2019. PMID: 31253690.
      16. Lin S, Sahai A, Chugh SS, Pan X, Wallner EI, Danesh FR, Lomasney JW, Kanwar YS. Withdrawal: High glucose stimulates synthesis of fibronectin via a novel protein kinase C, Rap1b, and B-Raf signaling pathway. J Biol Chem 294(26):10381, 2019. e-Pub 2019. PMID: 31253689.
      17. Galvan DL, Long J, Green N, Chang BH, Lin JS, Schumacker P, Truong LD, Overbeek P, Danesh FR. Drp1S600 phosphorylation regulates mitochondrial fission and progression of nephropathy in diabetic mice. J Clin Invest 130(7):2807-2823, 2019. e-Pub 2019. PMID: 31063459.
      18. Li Y, Hu Q, Li C, Liang K, Xiang Y, Hsiao H, Nguyen TK, Park PK, Egranov SD, Ambati CR, Putluri N, Hawke DH, Han L, Hung MC, Danesh FR, Yang L, Lin C. PTEN-induced partial epithelial-mesenchymal transition drives diabetic kidney disease. J Clin Invest 129(3):1129-1151, 2019. e-Pub 2019. PMID: 30741721.
      19. Long J, Danesh FR. Values and Limitations of Targeting lncRNAs in Diabetic Nephropathy. Diabetes 67(4):552-553, 2018. e-Pub 2018. PMID: 29559513.
      20. Galvan DL, Badal SS, Long J, Chang BH, Schumacker PT, Overbeek PA, Danesh FR. Real-time in vivo mitochondrial redox assessment confirms enhanced mitochondrial reactive oxygen species in diabetic nephropathy. Kidney Int 92(5):1282-1287, 2017. e-Pub 2017. PMID: 28754553.
      21. Galvan DL, Green NH, Danesh FR. The hallmarks of mitochondrial dysfunction in chronic kidney disease. Kidney Int 92(5):1051-1057, 2017. e-Pub 2017. PMID: 28893420.
      22. Wang W, Badal S, Wang Y, Long J, Wang J, Danesh FR. Real-Time In Vivo Mitochondrial Redox Assessment Confirms Enhanced Mitochondrial ROS in Diabetic Nephropathy. Kidney International 92:1282-1287, 2017. e-Pub 2017.
      23. Galvan DL, Danesh FR. β2-adrenergic receptors in inflammation and vascular complications of diabetes. Kidney Int 92(1):14-16, 2017. e-Pub 2017. PMID: 28646990.
      24. Doshi M, Lahoti A, Danesh FR, Batuman V, Sanders PW, Onco-Nephrology Forum ASON. Paraprotein-Related Kidney Disease: Kidney Injury from Paraproteins-What Determines the Site of Injury?. Clin J Am Soc Nephrol 11(12):2288-2294, 2016. e-Pub 2016. PMID: 27526707.
      25. Long J, Badal SS, Ye Z, Wang Y, Ayanga BA, Galvan DL, Green NH, Chang BH, Overbeek PA, Danesh FR. Long noncoding RNA Tug1 regulates mitochondrial bioenergetics in diabetic nephropathy. J Clin Invest 126(11):4205-4218, 2016. e-Pub 2016. PMID: 27760051.
      26. Ayanga BA, Badal SS, Wang Y, Galvan DL, Chang BH, Schumacker PT, Danesh FR. Dynamin-Related Protein 1 Deficiency Improves Mitochondrial Fitness and Protects against Progression of Diabetic Nephropathy. J Am Soc Nephrol 27(9):2733-47, 2016. e-Pub 2016. PMID: 26825530.
      27. Badal SS, Wang Y, Long J, Corcoran DL, Chang BH, Truong LD, Kanwar YS, Overbeek PA, Danesh FR. miR-93 regulates Msk2-mediated chromatin remodelling in diabetic nephropathy. Nat Commun 28(7):12076-82, 2016. e-Pub 2016. PMID: 27350436.
      28. Peng H, Cao J, Yu R, Danesh F, Wang Y, Mitch WE, Xu J, Hu Z. CKD Stimulates Muscle Protein Loss Via Rho-associated Protein Kinase 1 Activation. J Am Soc Nephrol 27(2):509-19, 2016. e-Pub 2016. PMID: 26054539.
      29. Badal SS, Danesh FR. Diabetic Nephropathy: Emerging Biomarkers for Risk Assessment. Diabetes 64(9):3063-5, 2015. e-Pub 2015. PMID: 26294427.
      30. Luo J, Liang M, Mitch WE, Danesh FR, Yu M, Cheng J. FSP-1 Impairs the Function of Endothelium Leading to Failure of Arteriovenous Grafts in Diabetic Mice. Endocrinology 156(6):2200-10, 2015. e-Pub 2015. PMID: 25774552.
      31. Badal SS, Danesh FR. MicroRNAs and their applications in kidney diseases. Pediatr Nephrol 30(5):727-40, 2015. e-Pub 2015. PMID: 24928414.
      32. Long J, Badal SS, Wang Y, Chang BH, Rodriguez A, Danesh FR. MicroRNA-22 is a Master Regulator of Bone Morphogenetic Protein-7/6 Homeostasis in the Kidney. J Biol Chem 288(51):36202-14, 2013. e-Pub 2013. PMID: 24163368.
      33. Wang W, He B, Shi W, Liang X, Ma J, Shan Z, Hu Z, Danesh FR. Deletion of scavenger receptor A protects mice from progressive nephropathy independent of lipid control during diet-induced hyperlipidemia. Kidney Int 81(10):1002-14, 2012. e-Pub 2012. PMID: 22377830.
      34. Wang W, Wang Y, Long J, Wang J, Haudek SB, Overbeek P, Chang BH, Schumacker PT, Danesh FR. Mitochondrial fission triggered by hyperglycemia is mediated by ROCK1 activation in podocytes and endothelial cells. Cell Metab 15(2):186-200, 2012. e-Pub 2012. PMID: 22326220.
      35. Bakota EL, Wang Y, Danesh FR, Hartgerink JD. Injectable multidomain peptide nanofiber hydrogel as a delivery agent for stem cell secretome. Biomacromolecules 12(5):1651-7, 2011. e-Pub 2011. PMID: 21417437.
      36. Long J, Wang Y, Wang W, Chang BH, Danesh FR. MicroRNA-29c is a signature microRNA under high glucose conditions that targets Sprouty homolog 1, and its in vivo knockdown prevents progression of diabetic nephropathy. J Biol Chem 286(13):11837-48, 2011. e-Pub 2011. PMID: 21310958.
      37. Wang Y, Bakota E, Chang BH, Entman M, Hartgerink JD, Danesh FR. Peptide nanofibers preconditioned with stem cell secretome are renoprotective. J Am Soc Nephrol 22(4):704-17, 2011. e-Pub 2011. PMID: 21415151.
      38. Long J, Wang Y, Wang W, Chang BH, Danesh FR. Identification of microRNA-93 as a novel regulator of vascular endothelial growth factor in hyperglycemic conditions. J Biol Chem 285(30):23457-65, 2010. e-Pub 2010. PMID: 20501654.
      39. Wang J, Wang Y, Long J, Chang BH, Wilson MH, Overbeek P, Danesh FR. Tamoxifen-inducible podocyte-specific iCre recombinase transgenic mouse provides a simple approach for modulation of podocytes in vivo. Genesis 48(7):446-51, 2010. e-Pub 2010. PMID: 20641128.
      40. Sun L, Xie P, Wada J, Kashihara N, Liu FY, Zhao Y, Kumar D, Chugh SS, Danesh FR, Kanwar YS. Rap1b GTPase ameliorates glucose-induced mitochondrial dysfunction. J Am Soc Nephrol 19(12):2293-301, 2008. e-Pub 2008. PMID: 18753253.
      41. Kolavennu V, Zeng L, Peng H, Wang Y, Danesh FR. Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control. Diabetes 57(3):714-23, 2008. e-Pub 2008. PMID: 18083785.
      42. Kanwar YS, Danesh FR, Chugh SS. Chimerism of the renal glomerulus revisited. J Am Soc Nephrol 18(8):2215-7, 2007. e-Pub 2007. PMID: 17625114.
      43. Xu H, Zeng L, Peng H, Chen S, Jones J, Chew TL, Sadeghi MM, Kanwar YS, Danesh FR. HMG-CoA reductase inhibitor simvastatin mitigates VEGF-induced "inside-out" signaling to extracellular matrix by preventing RhoA activation. Am J Physiol Renal Physiol 291(5):F995-1004, 2006. e-Pub 2006. PMID: 16774905.
      44. Xu H, Liu P, Liang L, Danesh FR, Yang X, Ye Y, Zhan Z, Yu X, Peng H, Sun L. RhoA-mediated, tumor necrosis factor alpha-induced activation of NF-kappaB in rheumatoid synoviocytes: inhibitory effect of simvastatin. Arthritis Rheum 54(11):3441-51, 2006. e-Pub 2006. PMID: 17075836.
      45. Tramonti G, Xie P, Wallner EI, Danesh FR, Kanwar YS. Expression and functional characteristics of tubular transporters: P-glycoprotein, PEPT1, and PEPT2 in renal mass reduction and diabetes. Am J Physiol Renal Physiol 291(5):F972-80, 2006. e-Pub 2006. PMID: 17028260.
      46. Nayak B, Xie P, Akagi S, Yang Q, Sun L, Wada J, Thakur A, Danesh FR, Chugh SS, Kanwar YS. Modulation of renal-specific oxidoreductase/myo-inositol oxygenase by high-glucose ambience. Proc Natl Acad Sci U S A 102(50):17952-7, 2005. e-Pub 2005. PMID: 16330753.
      47. Zeng L, Xu H, Chew TL, Eng E, Sadeghi MM, Adler S, Kanwar YS, Danesh FR. HMG CoA reductase inhibition modulates VEGF-induced endothelial cell hyperpermeability by preventing RhoA activation and myosin regulatory light chain phosphorylation. FASEB J 19(13):1845-7, 2005. e-Pub 2005. PMID: 16160062.
      48. Kanwar YS, Akagi S, Nayak B, Sun L, Wada J, Xie P, Thakur A, Chugh SS, Danesh FR. Renal-specific oxidoreductase biphasic expression under high glucose ambience during fetal versus neonatal development. Kidney Int 68(4):1670-83, 2005. e-Pub 2005. PMID: 16164644.
      49. Chen S, Lee JS, Iglesias-de la Cruz MC, Wang A, Izquierdo-Lahuerta A, Gandhi NK, Danesh FR, Wolf G, Ziyadeh FN. Angiotensin II stimulates alpha3(IV) collagen production in mouse podocytes via TGF-beta and VEGF signalling: implications for diabetic glomerulopathy. Nephrol Dial Transplant 20(7):1320-8, 2005. e-Pub 2005. PMID: 15840669.
      50. Zeng L, Xu H, Chew TL, Chisholm R, Sadeghi MM, Kanwar YS, Danesh FR. Simvastatin modulates angiotensin II signaling pathway by preventing Rac1-mediated upregulation of p27. J Am Soc Nephrol 15(7):1711-20, 2004. e-Pub 2004. PMID: 15213258.
      51. Zeng L, Kanwar YS, Amro N, Phillips C, Molitch M, Batlle D, Danesh FR. Epigenetic and genetic analysis of p16 in dermal fibroblasts from type 1 diabetic patients with nephropathy. Kidney Int 63(6):2094-102, 2003. e-Pub 2003. PMID: 12753296.
      52. Lin S, Sahai A, Chugh SS, Pan X, Wallner EI, Danesh FR, Lomasney JW, Kanwar YS. High glucose stimulates synthesis of fibronectin via a novel protein kinase C, Rap1b, and B-Raf signaling pathway. J Biol Chem 277(44):41725-35, 2002. e-Pub 2002. PMID: 12196513.
      53. Sun L, Pan X, Wada J, Haas CS, Wuthrich RP, Danesh FR, Chugh SS, Kanwar YS. Isolation and functional analysis of mouse UbA52 gene and its relevance to diabetic nephropathy. J Biol Chem 277(33):29953-62, 2002. e-Pub 2002. PMID: 12171997.
      54. Danesh FR, Sadeghi MM, Amro N, Philips C, Zeng L, Lin S, Sahai A, Kanwar YS. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/ p21 signaling pathway: Implications for diabetic nephropathy. Proc Natl Acad Sci U S A 99(12):8301-5, 2002. e-Pub 2002. PMID: 12048257.
      55. Danesh FR, Lynch P, Kanwar YS. Lupus membranous glomerulonephritis mimicking hepatitis C-associated nephropathy. Am J Kidney Dis 39(3):E19, 2002. e-Pub 2002. PMID: 11877599.
      56. Danesh FR, Ye M, Salmi S, Lapointe M, Batlle D. Temporal profile of serum-induced S-phase entry and retinoblastoma protein phosphorylation in human skin fibroblasts. Kidney Int 56(4):1282-5, 1999. e-Pub 1999. PMID: 10504475.
      57. Keilani T, Danesh FR, Schlueter WA, Molteni A, Batlle D. A subdepressor low dose of ramipril lowers urinary protein excretion without increasing plasma potassium. Am J Kidney Dis 33(3):450-7, 1999. e-Pub 1999. PMID: 10070908.
      58. Danesh FR, Batlle D. H+-ATPase in hyperkalemic distal renal tubular acidosis. Am J Kidney Dis 32(6):1091-5; discussion 1095-7, 1998. e-Pub 1998. PMID: 9856531.

      Review Articles

      1. Coellar JD, Long J, Danesh FR. Long Noncoding RNAs and Their Therapeutic Promise in Diabetic Nephropathy. Nephron:1-11. e-Pub 2021. PMID: 33853077.
      2. Galvan DL, Mise K, Danesh FR. Mitochondrial Regulation of Diabetic Kidney Disease. Front Med (Lausanne) 8:745279, 2021. e-Pub 2021. PMID: 34646847.
      3. Mise K, Galvan DL, Danesh FR. Shaping Up Mitochondria in Diabetic Nephropathy. Kidney360 1(9):982-992, 2020. e-Pub 2020. PMID: 34189465.
      4. Badal SS, Danesh FR. New insights into molecular mechanisms of diabetic kidney disease. Am J Kidney Dis 63(2 Suppl 2):S63-83, 2014. e-Pub 2014. PMID: 24461730.
      5. Kanwar YS, Wada J, Sun L, Xie P, Wallner EI, Chen S, Chugh S, Danesh FR. Diabetic nephropathy: mechanisms of renal disease progression. Exp Biol Med (Maywood) 233(1):4-11, 2008. e-Pub 2008. PMID: 18156300.
      6. Kanwar YS, Danesh FR, Chugh SS. Contribution of proteoglycans towards the integrated functions of renal glomerular capillaries: a historical perspective. Am J Pathol 171(1):9-13, 2007. e-Pub 2007. PMID: 17591948.
      7. Kanwar YS, Nayak B, Lin S, Akagi S, Xie P, Wada J, Chugh SS, Danesh FR. Hyperglycemia: its imminent effects on mammalian nephrogenesis. Pediatr Nephrol 20(7):858-66, 2005. e-Pub 2005. PMID: 15875217.
      8. Shah S, Paparello J, Danesh FR. Effects of statin therapy on the progression of chronic kidney disease. Adv Chronic Kidney Dis 12(2):187-95, 2005. e-Pub 2005. PMID: 15822054.
      9. Kanwar YS, Akagi S, Sun L, Nayak B, Xie P, Wada J, Chugh SS, Danesh FR. Cell biology of diabetic kidney disease. Nephron Exp Nephrol 101(3):e100-10, 2005. e-Pub 2005. PMID: 16088221.
      10. Danesh FR, Kanwar YS. Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy. FASEB J 18(7):805-15, 2004. e-Pub 2004. PMID: 15117885.
      11. Kanwar YS, Wada J, Lin S, Danesh FR, Chugh SS, Yang Q, Banerjee T, Lomasney JW. Update of extracellular matrix, its receptors, and cell adhesion molecules in mammalian nephrogenesis. Am J Physiol Renal Physiol 286(2):F202-15, 2004. e-Pub 2004. PMID: 14707006.
      12. Danesh FR, Wada J, Wallner EI, Sahai A, Srivastava SK, Kanwar YS. Gene regulation of aldose-, aldehyde- and a renal specific oxido reductase (RSOR) in the pathobiology of diabetes mellitus. Curr Med Chem 10(15):1399-406, 2003. e-Pub 2003. PMID: 12871137.
      13. Danesh FR, Anel RL, Zeng L, Lomasney J, Sahai A, Kanwar YS. Immunomodulatory effects of HMG-CoA reductase inhibitors. Arch Immunol Ther Exp (Warsz) 51(3):139-48, 2003. e-Pub 2003. PMID: 12894868.
      14. Danesh FR, Klinkmann J, Yokoo H, Ivanovich P. Fatal cervical spondyloarthropathy in a hemodialysis patient with systemic deposition of beta2-microglobulin amyloid. Am J Kidney Dis 33(3):563-6, 1999. e-Pub 1999. PMID: 10070922.

      Other Articles

      1. Mise, K, Long, J, Galvan, D, Ye, Z, Fan, G, Sharma, R, Serysheva, I, Moore, T, Jeter, CR, Anna Zal, M, Araki, M, Wada, J, Schumacker, PT, Chang, B, Danesh, FR Correction to. Nature communications 15(1), 2024. PMID: 38589378.

      Editorials

      1. Galvan DL, Danesh FR. Paradoxical Role of IL-17 in Progression of Diabetic Nephropathy. J Am Soc Nephrol 27(3):657-8, 2016. PMID: 26334029.
      2. Badal SS, Danesh FR. Strategies to reverse endothelial dysfunction in diabetic nephropathy. Kidney Int 82(11):1151-4, 2012. PMID: 23151985.
      3. Badal SS, Danesh FR. Managing microvascular complications of diabetes with microRNAs. J Am Soc Nephrol 23(2):185-7, 2012. PMID: 22241893.

      Abstracts

      1. Li L, Long J, Mise K, Poungavrin N, Lorenzi PL, Mahmud I, Tan L, Saha PK, Kanwar YS, Chang BH, Danesh FR. The transcription factor ChREBP links mitochondrial lipidomes to mitochondrial morphology and progression of diabetic kidney disease. J Biol Chem 299(9):105185, 2023. e-Pub 2023. PMID: 37611830.
      2. Long J, Wang Y, Wang W, Danesh FR. MicroRNA-29c targets sprouty1, promotes apoptosis and fibrosis, and its inhibition prevents progression of diabetic nephropathy. Anerican Society of Hephrology Annual Meeting, Oral Presentation, 2010. e-Pub 2010.
      3. Wang W, Wang Y, Long J, Danesh FR. Targeted deletion of ROCK1 confers renoprotection in diabetic nephropathy. American Society of Nephrology Annual Meeting, Oral Presentation, 2010. e-Pub 2010.
      4. Long J, Wang Y, Danesh FR. Identification of microRNA-93 as a novel regulator of vascular endothelial growth factr (VEGF) in hyperglycemic conditions. American Society of Nephrology Annual Meeting, Oral Presentation, 2010. e-Pub 2010.
      5. Long J, Wang Y, Danesh FR. Micromanaging VEGF by microRNA-93 in diabetes. American Society of Nephrology Annual Meeting, Oral Presentation, 2009. e-Pub 2009.
      6. Wang W, Shi W, Liang S, Yu X, FR D. Deletion of Scavenger Receptor A |/|| Ameliorates Tubulointerstitial Fibrosis in UUO Mice with Diet- Induced Hypercholesterolemia. American Society of Nephrology Annual Meeting, 2008. e-Pub 2008.
      7. Sun L, Xie P, Liu FU, Chugh SS, Danedh FR. Role of Rap1b GTPase in Modulation of High Glucose-Induced Renal Mitochondrial Injury. American Society of Nephrology Annual Meeting, 2008. e-Pub 2008.
      8. Wang Y, Zhang G, Wang W, Bakato EL, Crane AM, Hartgerink D, Danesh FR. Synthetic nanofibers confer renoprotection via delivery of cytokines released from embryonic stem cells. American Society of Nephrology, Annual Meeting, 2008. e-Pub 2008.

      Book Chapters

      1. Badal S, Danesh FR. Systems Biology of Free Radicals and Antioxidant. In: Reactive oxygen species and diabetic nephropathy. Spriger-Verlag Berlin Heidelberg, 2014.
      2. Paparello J, Danesh FR. Pier Module 11. In: Acute Glomerulonephritis. American College of Physicians, 2004.
      Read More
      Less

      Patient Reviews


      CV information above last modified July 22, 2026

      Request an Appointment

      Whether you are ready to make an appointment now or have questions for our expert team, we are standing by to help.
      Learn more

      Related Links

      • Danesh Lab

      • Internal Medicine Center

      • Internal Medicine Division

      Clinical Trials

      Our patients have access to clinical trials offering promising new treatments that cannot be found anywhere else.
      Learn more

      Help #EndCancer

      Give Now

      Your gift will help make a tremendous difference.
      Donate

      Donate Blood

      Our patients depend on blood and platelet donations.

      Make an appointment

      Shop UT MD Anderson

      Show your support for our mission through branded merchandise.

      View products
      Subscribe to our Cancerwise newsletter
      UT MD Anderson logoUT MD Anderson logo
      • Explore
      • Patients & Family
      • Prevention & Screening
      • Donors & Volunteers
      • For Physicians
      • Research
      • Education & Training
      • Clinical Trials
      • Languages
      • About
      • About UT MD Anderson
      • Careers
      • Blog
      • Newsroom
      • Editorial Standards
      • For Employees
      • Merchandise
      • Title IX Reporting (Sexual Misconduct)
      • Price Transparency
      • Finding Your Way
      • Our Doctors
      • Locations
      • Directions
      • Sitemap
      • DIGITAL ACCESSIBILITY
      • Accessibility Policy MD Anderson works with Level Access to ensure our website is accessible and functional for all users. Free assistive technology is provided for people with physical disabilities. To learn more or to download the assistive technology tool, visit https://www.levelaccess.com/MDAnderson
      • GET IN TOUCH
      • Call
        1-877-632-6789
      • Ask a question
      • Stay Connected
      • Cancerwise Podcast
      • More
      • Website Privacy Policy
      • Legal Statement & Policies
      • Reports to the State
      • Emergency Alert Information
      • State of Texas Links
      • Our Cancer Network
      • Vendors & Suppliers
      UT MD Anderson logo
      The mission of The University of Texas MD Anderson Cancer Center is to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public.

      © 2026 The University of Texas MD Anderson Cancer Center. All rights reserved.

      Top